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A similarity search on the structural analogs of an inhibitor of BACE-1 with IC50 2.8 μM, 1 
which contained a P1 benzothiazole group together with a triazine ring linked by a secondary 2 
amine group, was described in this letter and some more potent inhibitors against BACE-1 were 3 
identified. The most potent compound 5 (IC50 = 0.12 μM) increases the inhibitory potency by 24 4 
folds. Our results suggest that a pyrrolidinyl side group at the P3’ and P4’ of the inhibitors are 5 
favored for strong inhibition and a small aromatic group at the P4 position is also essential to the 6 
potency.  7 
















Alzheimer’s disease (AD) is a progressive neurodegenerative condition of the brain and 1 
represents the most common form of dementia1. AD patients show gradual loss of memory and 2 
cognitive ability. Today, it is affecting over 24 million in the world and the number is predicted 3 
to reach 80 million by 20402, 3. Currently, there is no treatment available for AD and medical 4 
therapies are usually limited to acetylcholinesterase inhibitors and NMDA antagonists4, 5. 5 
However, both of the two only marginally reduce the symptoms of AD but do no cure it 6 
thoroughly6. One of the major pathological hallmarks of AD is the deposition of the amyloid β 7 
peptide (Aβ40, 42) to form extracellular plaques in AD brain tissues
7. Aβ peptides are derived from 8 
the sequential cleavage on amyloid precursor protein (APP) by two aspartic acid proteases, 9 
namely β-secretase and γ-secretase8, 9. Although the cause of AD is not fully known to us, 10 
evidence is accumulating to highlight the important role of the Aβ in the pathogenesis of AD1, 10, 11 
11. Hence, inhibitors of either protease offer alluring potential disease-ameliorating candidates in 12 
the AD drug discovery campaign. Since the β-secretase (also called BACE-1 or β-site of APP 13 
cleaving enzyme) mediated cleavage of the APP is the first step in the generation of the Aβ, 14 
inhibition of BACE-1 is considered a more prominent target for treating AD1. Furthermore, the 15 
possibility of interruption of the Notch pathway by γ-secretase inhibitors renders γ-secretase a 16 
less attractive drug target4.  Over the past decade, many BACE-1 inhibitors have been reported 17 
and these inhibitors are mainly divided into two classes: peptidomimetic and non-18 
peptidomimetic inhibitors12-14. The peptidomimetic inhibitors were the analogs of the natural 19 
substrates of BACE-1 and these included hydroxyethylenes, statines, norstatines, 20 
hydroxyethylamines. Among them, the first potent inhibitor was the OM99-2 and it was co-21 
crystallised with the BACE-1 for resolving the 3-dimensional structure of the enzyme-inhibitor 22 





revealed and eight such pockets were known to be involved. Xiao et al employed a combinatorial 1 
chemistry approach to develop a homostatine based inhibitor which had an IC50 value of 143 nM 2 
in an enzymatic assay15 and the Shering-Plough Corp presented a hydroxyethylamine based 3 
inhibitor with an IC50 of 4 nM
16. Although peptidomimetic inhibitors showed potent activity 4 
against BACE-1, their relatively large molecular size, low metabolic stability and poor 5 
bioavailability render their development into therapeutic drug candidates difficult. On the other 6 
hand, a great deal of effort has been paid off to discover non-peptidic, organic compounds with 7 
better pharmacokinetic properties as drug leads. Some non-peptide compounds were identified as 8 
potent inhibitors of BACE-1. For a more detailed review on the non-peptidic inhibitors of 9 
BACE-1, refer to reference 4.  10 
 Previously we reported several non-peptidic inhibitors and to one of these inhibitors, the 11 
compound 117, based on the skeleton of which we performed a similarity search in the SPECS 12 
(www.specs.net) database and found some structurally similar compounds. Most of those 13 
compounds were tested to be active to inhibit BACE-1. Herein, the discovery, enzyme inhibition 14 
assays, and molecular docking of these analogs are outlined.  15 
Figure 1 summarises the whole process from our previous virtual screening leading to the 16 
present study. A 2-D similarity search was performed at the SPECS vendor’s website by keeping 17 
the scaffold shown in Table 1 and a cutoff similarity index was set to 70%. All the compounds 18 
were built using Sybyl 8.0 (Tripos associate inc., St. Louis, MO, USA) on an SGI machine.  19 
Gasteiger-Marsili charges were assigned to the molecules and the initially built structures were 20 
subjected to energy minimization using the Powell method by applying the termination gradient 21 
of 0.05kcal/mol for 100 maximum iterations. The crystal structure of BACE-1 complexed with 22 





Protein Data Bank (PDB) (www.rcsb.org/pdb). All hydrogen atoms were added and the water 1 
molecules co-crystallised with the protein were removed from the original structure using Sybyl. 2 
The modified crystal structure of BACE-1 was subjected for molecular docking using GOLD 3.0 3 
software (CCDC, Cambridge, U.K.). Docking of all the ligands was performed with the default 4 
docking settings. The active site radius was set at a distance of 12Ǻ from the atom number 1846 5 
of the Asp228, which is one of the key catalytic amino acid residues in the aspartyl protease. The 6 
GoldScore fitness function was applied. The population size was set to 100. The selection 7 
pressure was set to 1.1 and the number of operations was set at 100000. The Migration, mutation 8 
and cross over parameters were set to 10, 95, and 95 respectively. For shortening the docking 9 
speed, 10 conformations were applied for each ligand and the docking was allowed to stop when 10 
the RMSD value was within 1.5 Ǻ between the top 3 solutions of each ligand.  BACE-1 11 
inhibition assays were carried out using the Fluorescense Resonance Energy Transfer (FRET) 12 
assay kits according to the protocol described previously17. 13 
Table 1 lists the structures and inhibition results (IC50) of the 22 tested compounds. 14 
Except for 14, 17, 18, 20, 21, 22, all other compounds inhibited over 50% at the initially tested 15 
concentration of 50 μM. All the compounds mainly diverse in the R and X groups as labeled in 16 
Table 1. To elucidate the relationship between the binding modes of these inhibitors and their 17 
activities, molecular docking was carried out and the best scored conformation of each 18 
compound was aligned in the active binding site of BACE-1 (Figure 2). As docking algorithms 19 
are generally believed to produce good binding poses but lack accuracy in ranking these poses18 , 20 
to clarify the suitability of selecting the top scored docking pose for structural alignment, we 21 
further performed a comparison by calculating the RMSD values of the rest of the poses 22 





in Table 1 of the supplementary data. The RMSD values were lower than 2.0 Ǻ for nearly 90% of 1 
the compounds, indicating that it was reasonable for aligning the top scored conformation for 2 
further analysis. On a whole, the central benzothiazole sit in the region between S1 and S2 where 3 
the catalytic aspartic acid residues are present. To the prime side of the active site, the interaction 4 
was extended to the S3’ and S4’ sub-pockets via the two R groups on the 4- and 6- positions of 5 
the triazine ring. Structurally, there were 3 major types of R groups: pyrrolidinyl, piperidinyl, and 6 
morpholinyl. Interestingly, being same at the P1, the difference in P3’ and P4’ as characterized by 7 
the changes among the above three R groups rendered the inhibitors’ potencies change 8 
dramatically. The pyrrolidinyl compounds 2-8 performed best in the inhibition studies. 9 
Compounds 9-12 bearing the piperidinyl at the same positions didn’t show comparable potencies 10 
but had moderate inhibition against BACE-1. It was noticed that compound 9 which shares high 11 
similarity to 5 with the exception at the R groups dropped its potency by almost 40% at 50 μM. 12 
The steric factor could be an important factor conferring the lower activity of the piperidinyl 13 
series as the steric confliction resulted in unfavorable accommodation of the relatively larger 14 
rings at the S3’ and S4’ pockets where bulky amino acids such as Tyr71, Tyr197, Tyr198, Pro70, 15 
Ile126, Arg128, Glu125 are present. Another interesting observation was that the prime side of 16 
the active site of BACE-1 is electrostatically more negative. Hence the polarity present in the 17 
piperidinyl might not be tolerated well. As opposed to the above two classes, the morpholinyl 18 
containing compounds abolished the potencies significantly (as seen in 13-23). Among the 19 
pyrrolidinyl series, of the particular interest was that compounds 5 and 7 emerged as the two 20 
most potent inhibitors among all. 5 which has a phenyl acetamide group at the P4 position (IC50 21 
of 0.12 μM) was twenty-fold more potent than the starting compound 1. Comparing compounds 22 





inhibition potency. However, this was not observed for compound 2. The lower activity of 1 
compound 2 could be the lack of the NH linker as compared to others in the same series. 2 
Compound 7 with a furylmethyl acetamide increased potency by five-fold as compared to 1. 3 
Thus, a small aromatic group linked to the acetamide in the pyrrolidinyl series appeared to be 4 
unique to the improvement of the potency. Meanwhile, it is worth noting that the ‘X’ side chain 5 
of 7 is of comparable length to compound 3, yet IC50 of the former was 2.5-fold lower. The 6 
polarity conferred by the furyl moity in 7 might be preferred for accommodating in the S4 sub-7 
pocket near which the Thr 232 is present. Figure 3 shows the detailed docked binding 8 
conformation of the two most potent compounds: 5 and 7 in BACE-1. Notably, several hydrogen 9 
bond formations between both compounds and the active site residues were observed from 10 
docking. The linker NH between the benzothiazole and triazine was noticed to form a hydrogen 11 
bond with the OD2 oxygen of Asp 32. This H-bond is considered as indispensible to the strong 12 
binding of the target enzyme as previously described elsewhere 4, 19. The formation of such an H-13 
bond could possibly explain why this group of compounds appeared to show inhibitory activities 14 
against BACE-1. Another H-bond was also potentially predicted to be present between the 15 
nitrogen 3 of triazine and the hydroxyl hydrogen of Tyr 198. In addition, there was a third 16 
hydrogen-bond between the hydrogen atom from the acetamide and the carbonyl oxygen of Thr 17 
232 from docking simulation. The two pyrrolidinyls on the triazine were in close contact with 18 
Tyr 198 and Tyr 71 respectively and contributed to hydrophobic interactions within the region. 19 
Similarly, compound 7 almost “cloned” the interaction pattern of 2 with the active site of BACE-20 
1. The same H-bond was noticed from the linker NH and OD2 of Asp 32 whereas the acetamide 21 





observed for other inhibitors of BACE-119. Unlike the more solvent exposed P4 phenyl ring in 1 
the compound 2, the furyl ring in 7 was deeply docked into the S4 pocket of BACE-1. 2 
2 had an IC50 which was 10-fold less potent than that of 3, the presence of the NH group 3 
in 3 could possibly form the H-bond with the carbonyl oxygen of Thr 232. In Mok’s paper 4 
describing a series of non-peptide inhibitors from virtual screening20, the amide H of Thr 232 5 
was involved in a key hydrogen bond contributing to the binding of the inhibitor. The similar 6 
hydrogen bond involving Thr 232 was also reported by Congreve et al. Compounds 6 and 8 7 
showed similar potencies.  8 
In summary, a similarity search followed by bioassays on the structural analogs of a 9 
known inhibitor of BACE-1 rapidly prioritised more potent inhibitors of the target enzyme. Our 10 
results revealed that the pyrrolidinyls at the P3’ and P4’ positions of the inhibitors are more 11 
favored than the piperidinyls and morpholinyls. Among the pyrrolidinyl series compounds, a 12 
phenyl acetamide at P4 led to the best potency against BACE-1. The SAR study provided 13 
invaluable insight into the important chemical information contributing to the strong potency of 14 
BACE-1 inhibitors. Furthermore, our study provided a new direction to the fragment based drug 15 
discovery which is an emerging niche approach in the development of novel drugs by searching 16 
and linking small fragments together to achieve the best efficacy for the ligands. Encouraged by 17 
current knowledge, our effort in optimizing present sub-micromolar hits into more potent 18 
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Table 1. SAR of Substitution patterns of R and X.  5 
 
 






























































































aValues are means of duplicate measurements.  1 
bValues are expressed as mean of duplicate in one experiment. 2 






















Figure 3. Cartoon representation of BACE-1 active site. Key residues are shown in stick and colored by 2 
atom type. A) Molecular docking pose of compound 5. B) Molecular docking pose of compound 7. 3 
Potential hydrogen bonds are depicted in dot lines and distances are labeled. The binding mode was 4 
derived from GOLD and the picture was generated by Pymol software. 5 
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